陳昭岑臺灣大學：化學研究所楊易勳Yang, Yi-HsunYi-HsunYang2007-11-262018-07-102007-11-262018-07-102007http://ntur.lib.ntu.edu.tw//handle/246246/51716細菌對抗生素所產生的抗藥性從數十年前就不斷的增加, 但在此期間所對應的抗生素並沒有隨著抗藥性的增加而以相同的速度被發現並且應用在臨床上. 目前所使用的抗生素不是在數十年前就被發現並使用就是以現有的抗生素的結構為骨架而做修飾而來. 新藥引入的緩慢有部份是歸因於目前沒有一個有效的藥物篩選方法. 因此我們嘗試建構一個以螢光共振能量傳遞為原理的新的藥物篩選方法. 我們設計了以Lipid II為骨架的類似物並且在它的兩端加上螢光團. 兩個螢光團分別修飾在(L)賴氨酸的支鏈氨基上和萜;烯長碳鏈的末端. Lipid II的長碳鏈的長度是可以經由化學合成調整長度, 並且可以藉由調整長度來達到能量轉移效率的最佳化. 經由這樣的設計我們希望能夠建立一個能夠快速篩選醣基轉移酶;抑制劑的方法. 以楓基為輔助基來幫助達成的丙烯基和丙烯基的耦合反應被引用在合成路徑裡. 這幫助將來可以合成更多不同長度的長碳鏈萜;烯類並應用在這樣的篩選檢測裡.Bacterial drug resistance increased in decades. There are few drugs which were introduced clinically due to the lack of an efficient screen method. Therefore we attempt to develop a new assay detecting compound inhibitory property to GTase (glycosyltransferase) based on FRET (Fluorescence Resonance Energy Transfer). We have designed a Lipid II analogue with two fluorophores on two terminal of lipid II. The length of the lipid chain is tunable in order to find a proper length for our purpose. In this way, we want to develop a HPT (high throughput) assay to detect GTase inhibitors. Sulfonyl group assisted allyl-allyl coupling has been applied to the convenient and convergent synthetic route. It helps us to further synthesize tunable length of linear terpene chain for the screen assay.Table of contents Table of contents………………………………………………………I Figure index….………………………………………………………….IV Scheme index……………………………………………………….……V Table index………………………………………………………….…VIII Abbreviation…………………………………………………………….IX Chinese abstract…………………………………………………………XI English abstract……………………………………………...................XII Chapter 1 Introduction 1.1 Antibiotics and bacterial resistance…..............................................1 1.2 Peptidoglycan biosynthesis…………………………………………2 1.3 Total synthesis of Lipid II and its analogues……………………5 1.3.1Total synthesis of Lipid II………………………………………5 1.3.2 Fluorescence analogue of lipid II……………………………...9 1.3.3 Lipid chain variation of Lipid II analogues……………10 1.4 Introduction of Allyl-Allyl coupling………………………………17 1.4.1 Allylmagnesium (Grignard reaction) and Allylbarium……….17 1.4.2 Stille coupling………………………………………………...18 1.4.3 Thiophenyl assisted allyl-allyl coupling……………………...19 1.4.4 Sulfone assisted allyl-allyl coupling………………………….20 Chapter 2 Design and synthesis 2.1 The assay designed………………………………………….23 2.2 Design of target molecule………………………………………….26 2.3 Retrosynthetic analysis of heptaprenyl monophosphate fluorescent analogue…………………………………………………...27 2.4 Synthesis of nerol derivative N07 and geraniol derivative G03……………………………………………………………………...30 2.4.1 Synthesis of nerol derivative N07……………………….........30 2.4.2 Synthesis of geraniol derivative G03………………………...40 2.5 Synthesis of allyl sulfone G07 and N13...........................................41 2.6 Allyl-allyl coupling…………………………………………………42 2.6.1 Sulfone assisted allyl-allyl coupling………………………….42 2.6.2 Palladium-catalyzed desulfonylation of allylic sulfones……..43 2.6.3 Desulfonylation with dissolving metal, lithium and sodium…45 2.7 Second round of allyl-allyl coupling………………………………48 2.7 Conclusion…………………………………………………………49 Chapter 3 Experimental section 3.1 General description………………………………………….53 3.2 Synthetic routes and spectral data………………………….55 References……….……………………………………………………..87 Appendix……………………………………………………………...95 Figure index Figure 1.1 Three stages of peptidoglycan biosynthesis…………………..3 Figure 1.2 Intermediates of Lipid II total synthesis………………………9 Figure 1.3 Dependence on lipid length for compounds containing cis-allylic double bonds…………………………………………………14 Figure 1.4 Lipid I and its analogues.........................................................16 Figure 1.5 Natural Lipid II and its analogues…………………………...16 Figure 2.1 Heptaprenyl monophosphate and its fluorescent analogue (MANT-C30-OP)………………………………………………………26 Figure 2.2 1H NMR spectrum, chemical structure and NMR assignment of N07………………………………………………………………….34 Figure 2.3 NOESY of N07 from δ=1 to δ=5……………………………35 Figure 2.4 1H NMR spectra, chemical structure, and NMR assignment of N11 and its isomer………………………………………………………39 Figure 2.5 NMR spectra of separated compound from Pd/LiHBEt3……………………………………………………………...45 Scheme index Scheme 1.1 Transglycosylase transfers disaccharide to construct linear saccharide chain…………………………………………………………..4 Scheme 1.2 Retrosynthetic scheme of Lipid II…………………………...7 Scheme 1.3 Synthesis of protected muramic acid………………………..7 Scheme 1.4 Synthetic scheme of lipid II synthesis………………………8 Scheme 1.5 The dansylated Lipid II…………………………………….10 Scheme 1.6 Synthesis of various chain length lipid II analogues……….11 Scheme 1.7 Lipid I analogue 27-36 and Lipid II analogue 33a………...13 Scheme 1.8 When the Lipid II formed, UDP released and coupled two enzymatic reactions……………………………………………………..13 Scheme 1.9 Grignard reaction resulted to complex products…………...17 Scheme 1.10 Allylbarium as nucleophile provides potential condition for allyl-allyl coupling………………………………………………………18 Scheme 1.11 η3-Palladium complex formation…………………………19 Scheme 1.12 The preparation of allyl phenyl thioether, the following allyl-allyl coupling and deprotection……………………………………19 Scheme 1.13 Allyl ester and allyl sulfone assisted allyl-allyl coupling and removal of auxiliaries…………………………………………………...20 Scheme 1.14 Allyl sulfone assisted allyl-allyl coupling………………...21 Scheme 2.1 The schematic representation of the assay…………………23 Scheme 2.2 In the absence of inhibitors, the transglycosylase transfers the disaccharide from Lipid II to linear glycan chain………………………24 Scheme 2.3 In the presence of inhibitors, the transglycosylase is inhibited and the FRET is retained………………………………………………..24 Scheme 2.4 Enzymatically synthetic scheme of Lipid II analogue……..25 Scheme 2.5 MANT Lipid II analogue is further modified chemically to MANT-NBD Lipid II analogue……………………………………….25 Scheme 2.6 The retrosynthetic scheme of MANT-C30-OP……………28 Scheme 2.7 The retrosynthetic scheme of nerol derivative N07………..29 Scheme 2.8 The retrosynthetic scheme of geraniol derivative G03…….30 Scheme 2.9 Selective ozonalysis to O-acetyl geraniol………………….31 Scheme 2.10 The transition state of Wittig reaction…………………….33 Scheme 2.11 Corey-Kim condition yields oxidation product and chlorination product……………………………………………………..36 Scheme 2.12 Desulfonylation using Na/naphthalenide………………...46 Scheme 2.13 Summary of N07 synthetic scheme………………………50 Scheme 2.14 Summary of G07 synthetic scheme………………………51 Scheme 2.15 Synthetic route to triterpene derivative C08……………52 Table index Table 1.1 Percentage of peptidoglycan (cpm baseline material/total cpm) formed from radiolabel led compounds 21-26…………………………12 Table 1.2 The reaction rate (RFU/Min) and relative reaction rate of Lipid analogues………………………………………………………………..14 Table 2.1 Desulfonylation with Pd catalyst and LHBEt3……………….4414876441 bytesapplication/pdfen-US合成七異戊醇衍生物synthesisheptaprenol derivativethesishttp://ntur.lib.ntu.edu.tw/bitstream/246246/51716/1/ntu-96-R94223011-1.pdf